Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCA33890 vs Pembrolizumab in Resectable Locally Advanced Squamous Cell Carcinoma of the Head and Neck
NCT07876414Phase 2Not yet recruiting
- Sponsor
- GORTEC
- Start
- Feb 2027
- Primary completion
- Feb 2030
01
Overview
A Phase 2 trial of INCA-33890 in squamous cell carcinoma of the head and neck (HNSCC), sponsored by GORTEC. Planned start Feb 2027; status: not yet recruiting.
02
Drugs
INCA-33890
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT07876414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07876414.